Ex parte SCHENK et al. - Page 6




              Appeal No. 1995-1989                                                                                      
              Application 07/850,142                                                                                    

              as being based on a non-enabling disclosure when s/he has reason to conclude that one                     
              skilled in the art would be unable to carry out the claimed invention.                                    
              In re Buchner, 929 F.2d 660, 661, 18 USPQ2d 1331, 1332 (Fed. Cir. 1991).  Here, we                        
              do not find that the examiner has provided any reasons or factual basis as to why one skill               
              in the art would doubt the specification statements.  That is, the examiner has not provided              
              any reasons or factual basis to support her conclusion that the method of making                          
              monoclonal antibodies having the claimed properties as described on pp. 11-14 of the                      
              specification is not reproducible.   To the contrary, we find that she is shifting the burden to          
              the appellants to demonstrate, or to provide evidence, that their procedure is reproducible.              
              Accordingly, the rejection is reversed.                                                                   


                                       The Rejections under 35 U.S.C. § 103                                             
                     The examiner has premised her various conclusions of obviousness on the                            
              teachings of Behan, Sevier, Cooper and the Sigma catalog.  However, we agree with  the                    
              appellants that none of the cited references teaches or suggests the claimed                              
              (i) diagnostic method, (ii) monoclonal antibodies having the specified binding                            
              characteristics, or (iii) kits for diagnosing AD which employ said monoclonals.  In our                   
              review of the applied prior art we do not find that any of the references even allude to                  
              monoclonal antibodies which bind specifically, and to a statistically greater degree, to                  
              acute phase reactant antigens in a sample derived from a subject having AD than to a                      

                                                           6                                                            





Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007